ES2172303T3 - Agentes terapeuticos obtenidos por catalisis enzimatica. - Google Patents
Agentes terapeuticos obtenidos por catalisis enzimatica.Info
- Publication number
- ES2172303T3 ES2172303T3 ES99904195T ES99904195T ES2172303T3 ES 2172303 T3 ES2172303 T3 ES 2172303T3 ES 99904195 T ES99904195 T ES 99904195T ES 99904195 T ES99904195 T ES 99904195T ES 2172303 T3 ES2172303 T3 ES 2172303T3
- Authority
- ES
- Spain
- Prior art keywords
- cell
- prodrug
- endogenous
- therapeutic agents
- selective substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Abstract
Compuesto que tiene la estructura: o una de sus sales, éteres o ésteres farmacéuticamente aceptables.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7226498P | 1998-01-23 | 1998-01-23 | |
US7695098P | 1998-03-05 | 1998-03-05 | |
US10863498P | 1998-11-16 | 1998-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2172303T3 true ES2172303T3 (es) | 2002-09-16 |
Family
ID=27372051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99904195T Expired - Lifetime ES2172303T3 (es) | 1998-01-23 | 1999-01-22 | Agentes terapeuticos obtenidos por catalisis enzimatica. |
Country Status (16)
Country | Link |
---|---|
US (3) | US6339151B1 (es) |
EP (2) | EP1167972B1 (es) |
JP (2) | JP2002500880A (es) |
CN (1) | CN1192102C (es) |
AT (1) | ATE212661T1 (es) |
AU (1) | AU753155B2 (es) |
BR (1) | BR9907736A (es) |
CA (1) | CA2317505C (es) |
DE (1) | DE69900841T2 (es) |
DK (1) | DK1045897T3 (es) |
ES (1) | ES2172303T3 (es) |
HK (2) | HK1039520A1 (es) |
IL (1) | IL137164A0 (es) |
PT (1) | PT1045897E (es) |
TW (1) | TWI244924B (es) |
WO (1) | WO1999037753A1 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0806956T3 (da) | 1995-02-01 | 2003-01-06 | Resprotect Gmbh | Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling |
US7875733B2 (en) * | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
AU9016998A (en) * | 1997-08-08 | 1999-03-01 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
CN1192102C (zh) * | 1998-01-23 | 2005-03-09 | 新生物生物公司 | 酶催化的治疗剂 |
BR0012677A (pt) * | 1999-07-22 | 2003-07-01 | Newbiotics Inc | Ativação terapêutica catalisada por enzima |
CN1391487A (zh) * | 1999-07-22 | 2003-01-15 | 新生物公司 | 酶催化的抗一感染治疗剂 |
JP2003525866A (ja) * | 1999-07-22 | 2003-09-02 | ニューバイオティックス インコーポレイテッド | 治療抵抗性腫瘍を処置するための方法 |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US6673564B2 (en) * | 1999-10-18 | 2004-01-06 | Millennium Pharmaceuticals, Inc. | Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
WO2001045690A2 (en) * | 1999-12-23 | 2001-06-28 | Newbiotics, Inc. | Use of bvdu for inhibiting the growth of hyperproliferative cells |
US20030212037A1 (en) * | 2000-12-21 | 2003-11-13 | Christopher Boyer | Use of bvdu for inhibiting the growth of hyperproliferative cells |
US20030130179A1 (en) * | 2000-07-20 | 2003-07-10 | Shepard H. Michael | Methods for identifying therapeutic targets for treating infectious disease |
WO2002007780A2 (en) * | 2000-07-20 | 2002-01-31 | Newbiotics, Inc. | Methods for identifying therapeutic targets |
CZ304734B6 (cs) * | 2000-07-21 | 2014-09-10 | Gilead Sciences, Inc. | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu |
US7138388B2 (en) * | 2001-01-19 | 2006-11-21 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
WO2002089739A2 (en) * | 2001-05-09 | 2002-11-14 | Newbiotics, Inc. | Peptide deformylase activated prodrugs |
US20030212147A1 (en) * | 2001-07-12 | 2003-11-13 | Chung Sum Man Stephen | Enzyme activated chemotherapy of liver cancer |
US20040235761A1 (en) * | 2001-08-14 | 2004-11-25 | Yousuke Furuta | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
EP1492523A2 (en) * | 2001-11-23 | 2005-01-05 | Chugai Seiyaku Kabushiki Kaisha | Method for identification of tumor targeting enzymes |
US20030152747A1 (en) * | 2002-01-11 | 2003-08-14 | The Garland Company, Inc., An Ohio Corporation | Roofing materials |
MXPA04010230A (es) * | 2002-04-18 | 2005-06-08 | Celmed Oncology Usa Inc | Profarmacos de peptido deformilasa activada. |
EP1585751A4 (en) * | 2002-11-14 | 2008-08-13 | Celmed Oncology Usa Inc | PEPTIDE DEFORMYLASE-ACTIVATED PRODRUGS |
EP1599484A2 (en) * | 2003-02-21 | 2005-11-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
CA2536357A1 (en) * | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
GB0401088D0 (en) * | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
TWI351284B (en) * | 2004-04-09 | 2011-11-01 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrugs |
US7309589B2 (en) | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
US20070010477A1 (en) * | 2005-04-07 | 2007-01-11 | Dolnick Bruce J | Acyl homoserine lactones for inhibition of cell growth |
WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
EP1938823A1 (en) * | 2005-10-19 | 2008-07-02 | Chugai Seiyaku Kabushiki Kaisha | Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble prodrug |
CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
DE102006037786A1 (de) * | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CN102481334B (zh) * | 2009-06-22 | 2013-12-18 | 健康研究股份有限公司 | 前药抗癌治疗 |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
AU2011329854B2 (en) | 2010-11-16 | 2017-03-30 | University Of Southern California | CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
KR101969333B1 (ko) * | 2011-02-18 | 2019-04-16 | 더 유에이비 리서치 파운데이션 | 푸린 뉴클레오시드 포스포릴라아제 또는 뉴클레오시드 하이드롤라아제 프로드러그의 증강된 치료적 용도 |
SG192841A1 (en) * | 2011-03-01 | 2013-09-30 | Nucana Biomed Ltd | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
MD4589C1 (ro) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
AU2013346515B2 (en) | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US20140309164A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
US9828409B2 (en) * | 2014-03-19 | 2017-11-28 | Minghong Zhong | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides |
TWI695718B (zh) | 2014-06-25 | 2020-06-11 | 英商努卡那公眾有限公司 | 前藥 |
TWI674097B (zh) | 2014-06-25 | 2019-10-11 | 英商努卡那公眾有限公司 | 磷酸酯衍生物之調配物 |
WO2016057825A1 (en) * | 2014-10-08 | 2016-04-14 | Epigenetics Pharma Llc | Vitamin e-nucleoside prodrugs |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
CN109207551B (zh) * | 2017-07-07 | 2023-05-26 | 上海睿智化学研究有限公司 | 一种筛选叶酸代谢相关药物的方法 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB982776A (en) * | 1962-01-24 | 1965-02-10 | Wellcome Found | 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity |
JPS5017989B1 (es) * | 1970-12-24 | 1975-06-25 | ||
US4267171A (en) | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
US4247544A (en) | 1979-07-02 | 1981-01-27 | The Regents Of The University Of California | C-5 Substituted uracil nucleosides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
JPS5843993A (ja) | 1981-09-09 | 1983-03-14 | Yamasa Shoyu Co Ltd | 1−β−D−アラビノフラノシル−(E)−5−(2−ハロゲノビニル)ウラシル−5′−りん酸およびその製造法 |
EP0095294A1 (en) | 1982-05-22 | 1983-11-30 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
DE3229169A1 (de) | 1982-08-05 | 1984-02-09 | Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen | Verwendung von 5-alkylpyrimidinnukleosiden und deren derivate als zytostatika |
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
RO88451A2 (ro) | 1984-06-05 | 1986-01-30 | Intreprinderea De Antibiotice,Ro | Derivati ai acidului 7-aminocefalosporanic si procedeu de preparare aacestora |
US5070082A (en) | 1986-10-23 | 1991-12-03 | American Cyanamid Company | Solubilized pro-drugs |
US5077282A (en) | 1986-10-23 | 1991-12-31 | American Cyanamid Company | Solubilized pro-drugs |
US5212291A (en) | 1986-10-23 | 1993-05-18 | American Cyanamid Company | Anthracycline derivatives as solubilized pro-drugs |
US5116827A (en) | 1986-10-23 | 1992-05-26 | American Cyanamid Company | Quinolinecarboxylic acid derivatives as solubilized pro-drugs |
US5077283A (en) * | 1986-10-23 | 1991-12-31 | American Cyanamid Company | Solubilized imidazole pro-drugs |
US5116822A (en) | 1986-10-24 | 1992-05-26 | Stichting Rega Vzw | Therapeutic application of dideoxycytidinene |
US4963533A (en) | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
NL8700366A (nl) | 1987-02-13 | 1988-09-01 | Stichting Rega V Z W | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
US5085983A (en) | 1988-08-19 | 1992-02-04 | City Of Hope | Detection of human tumor progression and drug resistance |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
EP0311108A3 (en) | 1987-10-08 | 1990-04-04 | Stichting REGA V.Z.W. | Anti-hiv active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside |
EP0311107A3 (en) | 1987-10-08 | 1990-04-18 | Stichting REGA V.Z.W. | Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides |
US4963263A (en) | 1988-03-24 | 1990-10-16 | Terrapin Technologies, Inc. | Method of identity analyte-binding peptides |
US5300425A (en) | 1987-10-13 | 1994-04-05 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
US5217869A (en) | 1987-10-13 | 1993-06-08 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
US5338659A (en) | 1991-04-02 | 1994-08-16 | Terrapin Technologies, Inc. | Method for determining analyte concentration by cross-reactivity profiling |
US5133866A (en) | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
EP0316592A3 (en) | 1987-11-13 | 1990-09-19 | Stichting REGA V.Z.W. | 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application |
CA1317291C (en) | 1987-12-14 | 1993-05-04 | Naeem Botros Hanna | Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds |
DE68917479D1 (de) * | 1988-02-24 | 1994-09-15 | Inst Rech Chim Biolog | Derivate von deoxy-2'-uridin substituiert in der 5, 3' oder 5' stellung durch acylierte alpha-amino-gruppen, verfahren zur herstellung und arzneimittel daraus. |
WO1990003978A1 (en) | 1988-10-03 | 1990-04-19 | Stichting Rega Vzw | 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application |
US5596018A (en) | 1988-12-28 | 1997-01-21 | Toray Industries, Inc. | Antiviral agents against aids-causing virus |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
SK280313B6 (sk) | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
GB9010242D0 (en) | 1990-05-08 | 1990-06-27 | British Telecomm | Optical signal regenerator and optical communications system incorporating same |
US5137724A (en) | 1990-05-23 | 1992-08-11 | Stichting Rega Vzw | Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5608046A (en) * | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
JPH06507549A (ja) | 1991-04-29 | 1994-09-01 | テラピン テクノロジーズ,インコーポレイテッド | 異常細胞のプロフィール作成および治療方法 |
US5556942A (en) | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
US5645988A (en) | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
SK279262B6 (sk) | 1991-05-16 | 1998-08-05 | Glaxo Group Limited | Protivírusová zmes, farmaceutický prostriedok s je |
DE69120069T2 (de) | 1991-09-04 | 1996-10-02 | Stichting Rega V Z W | Substituierte Nukleosidderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
US5233031A (en) * | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
US5879700A (en) | 1991-10-15 | 1999-03-09 | Hostetler; Karl Y. | Nucleoside analogue phosphates for topical use |
US5274162A (en) | 1991-12-13 | 1993-12-28 | Arnold Glazier | Antineoplastic drugs with bipolar toxification/detoxification functionalities |
EP0619736A1 (en) * | 1991-12-31 | 1994-10-19 | Worcester Foundation For Biomedical Research, Inc. | Antiparasitic oligonucleotides active against drug resistant malaria |
US5430148A (en) | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
US5668828A (en) * | 1992-05-08 | 1997-09-16 | Sanconix, Inc. | Enhanced frequency agile radio |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US5516631A (en) | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
IL105244A (en) * | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
US5502037A (en) | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
EP0720615B1 (en) * | 1993-09-21 | 2000-07-26 | Amersham Pharmacia Biotech UK Limited | Elongation, amplification and sequence determination using a chimeric oligonucleotide |
US5908919A (en) | 1993-10-01 | 1999-06-01 | Terrapin Technologies | Urethane mediated, GST specific molecular release systems |
GB9323008D0 (en) | 1993-11-05 | 1994-01-05 | Connors Thomas | Improvements relating to cancer therapy |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5521161A (en) | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
GB9415167D0 (en) * | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
US5556992A (en) * | 1994-09-02 | 1996-09-17 | Universite De Montreal | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5968910A (en) | 1994-11-30 | 1999-10-19 | Jan M. R. Balzarini | Compositions containing two or three inhibitors of different HIV reverse transcriptases |
DK0806956T3 (da) | 1995-02-01 | 2003-01-06 | Resprotect Gmbh | Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling |
US5705336A (en) | 1995-03-07 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Assay for sensitivity of tumors to DNA-platinating chemotherapy |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
IL117940A (en) | 1995-04-19 | 2003-06-24 | Kumiai Chemical Industry Co | Benzylsulfide derivatives, process for their production and insecticide compositions containing them |
US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
US5998151A (en) | 1995-12-01 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase |
WO1997021452A2 (en) | 1995-12-14 | 1997-06-19 | Advanced Magnetics, Inc. | Macromolecular prodrugs of nucleotide analogs |
US5880097A (en) | 1996-01-04 | 1999-03-09 | Terrapin Techologies, Inc. | Tethered prodrugs |
AU1846297A (en) * | 1996-01-31 | 1997-08-22 | Regents Of The University Of California, The | Method for inhibiting tumor cell growth |
RU2111970C1 (ru) | 1996-06-25 | 1998-05-27 | Иван Игоревич Федоров | 3'-оксимино-2',3'-дидезоксинуклеозиды |
GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
WO1999006072A1 (en) | 1997-07-30 | 1999-02-11 | Boehringer Mannheim Corporation | Cyclized prodrugs |
AU9016998A (en) * | 1997-08-08 | 1999-03-01 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
CA2307807C (en) | 1997-10-23 | 2008-09-02 | Andrea G. Bodnar | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
AU758426B2 (en) | 1997-10-30 | 2003-03-20 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Nucleosides for imaging and treatment applications |
CN1192102C (zh) * | 1998-01-23 | 2005-03-09 | 新生物生物公司 | 酶催化的治疗剂 |
GB9821121D0 (en) | 1998-09-29 | 1998-11-25 | James Robinson Ltd | Grey colouring photochromic fused pyrans |
DK1144011T3 (da) | 1998-12-11 | 2010-07-05 | Coulter Pharm Inc | Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf |
US6683061B1 (en) * | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
BR0012677A (pt) * | 1999-07-22 | 2003-07-01 | Newbiotics Inc | Ativação terapêutica catalisada por enzima |
WO2001007888A2 (en) | 1999-07-23 | 2001-02-01 | Westinghouse Electric Company Llc | Pulsed gamma neutron activation analysis (pgnaa) method and apparatus for nondestructive assay of containerized contaminants |
US6294546B1 (en) | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
GB0009486D0 (en) | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
GB0011203D0 (en) | 2000-05-09 | 2000-06-28 | Univ Cardiff | Chemical compounds |
US20020147175A1 (en) * | 2000-11-16 | 2002-10-10 | Shepard H. Michael | Synergistic ECTA compositions |
US7138388B2 (en) * | 2001-01-19 | 2006-11-21 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
-
1999
- 1999-01-22 CN CNB998032212A patent/CN1192102C/zh not_active Expired - Lifetime
- 1999-01-22 DE DE69900841T patent/DE69900841T2/de not_active Expired - Lifetime
- 1999-01-22 EP EP01120242.1A patent/EP1167972B1/en not_active Expired - Lifetime
- 1999-01-22 US US09/235,961 patent/US6339151B1/en not_active Expired - Lifetime
- 1999-01-22 WO PCT/US1999/001332 patent/WO1999037753A1/en active IP Right Grant
- 1999-01-22 PT PT99904195T patent/PT1045897E/pt unknown
- 1999-01-22 IL IL13716499A patent/IL137164A0/xx unknown
- 1999-01-22 AU AU24646/99A patent/AU753155B2/en not_active Expired
- 1999-01-22 ES ES99904195T patent/ES2172303T3/es not_active Expired - Lifetime
- 1999-01-22 AT AT99904195T patent/ATE212661T1/de active
- 1999-01-22 DK DK99904195T patent/DK1045897T3/da active
- 1999-01-22 EP EP99904195A patent/EP1045897B1/en not_active Expired - Lifetime
- 1999-01-22 JP JP2000528661A patent/JP2002500880A/ja active Pending
- 1999-01-22 US US09/235,809 patent/US6245750B1/en not_active Expired - Lifetime
- 1999-01-22 TW TW088101009A patent/TWI244924B/zh not_active IP Right Cessation
- 1999-01-22 BR BR9907736-1A patent/BR9907736A/pt not_active Application Discontinuation
- 1999-01-22 CA CA2317505A patent/CA2317505C/en not_active Expired - Lifetime
-
2000
- 2000-11-08 JP JP2000339831A patent/JP3265304B2/ja not_active Expired - Lifetime
-
2001
- 2001-02-08 HK HK02101070.9D patent/HK1039520A1/zh unknown
- 2001-02-08 HK HK01100891A patent/HK1030624A1/xx not_active IP Right Cessation
- 2001-02-12 US US09/782,721 patent/US7601703B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3265304B2 (ja) | 2002-03-11 |
CA2317505A1 (en) | 1999-07-29 |
US7601703B2 (en) | 2009-10-13 |
US20010034440A1 (en) | 2001-10-25 |
EP1167972A3 (en) | 2006-05-24 |
EP1045897A4 (en) | 2000-10-25 |
AU753155B2 (en) | 2002-10-10 |
EP1045897A1 (en) | 2000-10-25 |
EP1167972A2 (en) | 2002-01-02 |
CN1192102C (zh) | 2005-03-09 |
TWI244924B (en) | 2005-12-11 |
IL137164A0 (en) | 2001-07-24 |
ATE212661T1 (de) | 2002-02-15 |
EP1045897B1 (en) | 2002-01-30 |
PT1045897E (pt) | 2002-07-31 |
DE69900841T2 (de) | 2002-10-02 |
DE69900841D1 (de) | 2002-03-14 |
AU2464699A (en) | 1999-08-09 |
WO1999037753A1 (en) | 1999-07-29 |
BR9907736A (pt) | 2000-10-17 |
US6245750B1 (en) | 2001-06-12 |
EP1167972B1 (en) | 2017-03-08 |
CA2317505C (en) | 2011-01-04 |
JP2002500880A (ja) | 2002-01-15 |
DK1045897T3 (da) | 2002-05-13 |
CN1291228A (zh) | 2001-04-11 |
HK1030624A1 (en) | 2001-05-11 |
JP2001220397A (ja) | 2001-08-14 |
HK1039520A1 (zh) | 2002-04-26 |
US6339151B1 (en) | 2002-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2172303T3 (es) | Agentes terapeuticos obtenidos por catalisis enzimatica. | |
EP1004022A4 (en) | METHODS AND COMPOSITIONS FOR OVERCOMING RESISTANCE TO BIOLOGICAL THERAPY AND CHEMOTHERAPY | |
WO2019040935A8 (en) | Evolution of bont peptidases | |
IL195605A0 (en) | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | |
DE69737684D1 (de) | Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika | |
SE8800238L (sv) | Flytande enzymkompositioner | |
WO2004108139A3 (en) | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer | |
WO2005083086A3 (en) | Epha4 as therapeutic target of prc and pdaca | |
NO20015814D0 (no) | Metallkompleksforbindelser | |
BR0014758A (pt) | Sistemas e métodos para expressão de proteìna com alto rendimento | |
BR0012676A (pt) | Métodos para tratamento de tumores resistentes a terapia | |
EA200900425A1 (ru) | Способ повышения толерантности растений | |
BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
KR937003465A (ko) | 효소를 사용한 생가죽 라이밍 및 드렌칭 방법 | |
WO2006128084A3 (en) | Trps1-mediated modulation of hair growth | |
EP1240922A3 (en) | Methods and compositions for overcoming resistance to biologic and chemotherapy | |
BR0115728A (pt) | Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata | |
BR0113002A (pt) | Composição pronta para o uso, processo de descoloração das fibras queratìnicas humanas naturalmente pigmentadas, e dispositivo com vários compartimentos | |
WO2003038051A3 (en) | Method of inducing apoptosis in hyperproliferative cells | |
ATE382062T1 (de) | Antikörper gegen allgegenwärtige mitochondriale kreatinkinase und dessen verwendung | |
ATE264387T1 (de) | Verfahren zur auslösung von apoptose in zellen | |
WO2007047741A3 (en) | Expression of rbap48 in memory and aging and methods related thereto | |
EP1370679A4 (en) | MANUFACTURING METHOD AND USES FOR A COMPOSITION MODULATING INTRONICALLY PROTEIN FUNCTION | |
WO2003106627A3 (en) | CANCER-RELATED GENE GENE USED AS A TARGET FOR CHEMOTHERAPY | |
CY1110496T1 (el) | Σεκρεταση νοσου alzheimer, υποστρωματα app αυτης, και χρησεις αυτης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 1045897 Country of ref document: ES |